Explore BrainMass

Business Ethics of Retail Pharmaceutical Firms

This content was STOLEN from BrainMass.com - View the original, and get the already-completed solution here!

TOPICS: Business Ethics, cigarette, CVS, Health
SUMMARY: CVS, the nation's second-largest pharmacy chain, said Wednesday that it would stop selling all cigarettes and tobacco products nationwide by October, saying they have no place in a drugstore company that is trying to become more of a health-care provider. The move is a bold and expensive one for CVS, a unit of Woonsocket, R.I.-based CVS Caremark Corp. It reflects a major push by retail pharmacies away from simply dispensing drugs toward a more integrated role of providing basic health services to Americans-including millions of newly insured-amid an expected shortage of primary care doctors. The news is another blow to the $100 billion tobacco industry that is wrestling with slumping sales, rising taxes, widening smoking bans and a resurgence of public information campaigns highlighting the perils of smoking. For CVS, the move will be costly. The drugstore chain estimates it will lose $2 billion in annual revenue from tobacco and other sundries as a result, which amounts to about six to nine cents a share this year and about 17 cents annually from next year on. CVS, with annual revenue of more than $123 billion, projects its 2014 earnings will be $4.36 to $4.50 a share. But it is banking the strategy will give it a competitive edge over rival pharmacies in forging partnerships with hospitals, insurers and physician groups. These types of alliances are critical to drugstores like CVS and Walgreen Co. as they redefine themselves in what has been a historic downturn in prescription drug sales. CVS sees its future in making its in-store clinics a convenient health-care alternative to long waits at the doctor's office, along with CVS pharmacists counseling patients. That strategy was increasingly at odds with racks of cigarettes, cigars and chewing-tobacco residing behind the cashier's counter, said Larry Merlo, chief executive, in an interview. "Cigarettes have no place in an environment where health care is being delivered," said Mr. Merlo, a 58-year-old former pharmacist who became CEO of CVS Caremark in 2011. "This is the right decision at the right time as we evolve from a drugstore into a health-care company."
CLASSROOM APPLICATION: The nation's second largest pharmacy will stop selling cigarettes, putting pressure on rivals Walgreens, Rite Aid Corporation, and even Walmart stores to adopt similar measures. CVS is counting on consumers wanting to do business with a pharmacy focused on improving health and providing products associated with that of a healthcare provider. The company will not only dispense drugs to make people well but wants to use the shelf space to provide other healthcare products. The move will cost the drug store about $2 billion in revenue, but it is banking on stakeholder support from hospitals, insurers, and position groups. CVS's stock dropped about 3 percent in the first few days after the announcement, but the company is not worried because it feels that it is gaining a competitive advantage in positioning.

1. Will CVS's competitors stop selling cigarettes, or will they take advantage of a market opportunity since many of their stores are located very close to CVS stores?

2. Do you believe that a firm should sell a product that causes major health risks in a store that is positioned to help people manage and improve their health?

© BrainMass Inc. brainmass.com October 16, 2018, 5:29 pm ad1c9bdddf

Solution Preview

1. Will CVS's competitors stop selling cigarettes, or will they take advantage of a market opportunity since many of their stores are located very close to CVS stores?

CVS appears to be making a strategic move with halting sales of tobacco products at its stores. Their CEO hints at this with his statement "This is the right decision at the right time as we evolve from a drugstore into a health-care company." Also consider CVS recent acquisition of prescription drug benefits provider Caremark It does appear that CVS is trying to brand itself as a wellness company. I do not expect its competitors to follow suite unless they too are looking to change their business model because I am pretty skeptical that it will over time improve their bottom line profitability. I would anticipate that competitors of CVS are sure to benefit from this move in the short run. Many ...

Solution Summary

A look at the business impacts of CVS Pharmacy announcing it will no longer sell tobacco products. Discusses ethical issues of a healthcare provider selling products they may be harmful to ones health.

Similar Posting

International Legal and Ethical Issues: How mergers and acquisitions have affected business

Antitrust laws were essentially created to stop businesses that got too large from blocking competition and abusing their power. Mergers and monopolies can limit the choices offered to consumers because smaller businesses are not usually able to compete. Although free and open competition ensures lower prices and new and better products, it has the potential to significantly limit market diversity.

Look at the 2 examples below of how mergers and acquisitions have affected the way in which companies do business.

Read each of the 2 examples below. Decide which one you would like to use for this project and prepare an APA formatted research paper that responds to the aligned questions. Specifically, this paper must:
1) Identify the two firms with similar problems from different countries
2) Conduct a comparative analysis of the firms
3) Analyze political, social, ethical and legal differences and their impact on management decision making
4) Provide substantive conclusion and recommendations

Example 1

Federal antitrust enforcers are investigating whether a multinational pharmaceutical company has attempted to minimize the impact of generic competition to one of its most profitable prescription drugs. This anti-depressant drug is the company's best seller, with sales last year of $2.11 billion, representing a 22% increase from the year before.

The Federal Trade Commission (FTC) is conducting an investigation to determine whether the company has engaged in activities to prevent generic alternatives to the prescription drug from entering the market. Specifically, the FTC is challenging a practice among brand-name and generic-drug manufacturers to agree to delay the introduction of the lower priced generic drugs to the market.

Answer the following questions:
Why would the drug maker want to stymie generic competition? Explain.
What types of legal barriers to market entry exist?
What are the possible ethical dilemmas present in this example?

Example 2

The boards of 2 major telecommunications companies recently agreed to a $16 billion-dollar merger that would create the world's largest telecommunications company in the world. Although some agree that the synergy between these companies could be dynamic, others feel consumers could ultimately pay the price for the merger depending on which company becomes dominant in the various service areas.

Answer the following questions:
Why do you think consumer advocates have expressed concern over such merger possibilities?
Other than pricing, what are some pitfalls that consumers might have to deal with when 2 major companies merge?
What are the possible ethical dilemmas present in this example?

View Full Posting Details